- Thyroid nodules with an Atypia of Undetermined Significance (B-III) or Follicular Neoplasm (B-IV) cytology diagnosis present a broad and uncertain risk of malignancy, complicating clinical decision-making regarding appropriate treatment1
- Molecular testing is routinely utilized to refine risk stratification in indeterminate cytology cases1,2
- This study included a retrospective analysis of ThyGeNEXT® + ThyraMIR®v2 test results from a large series of clinical cases
- The goal was to determine the impact of microRNA expression profiling on improving the risk of malignancy assessment in a large cohort of thyroid nodules classified as Bethesda III or Bethesda IV
Refined Risk Stratification of Bethesda III/IV Thyroid Nodules Using ThyGeNEXT and ThyraMIRv2
ATA Annual Meeting, 2025
Patient management decisions are based on the independent medical judgment of the physician and molecular test results should be taken into consideration in conjunction with all relevant imaging, clinical findings, patient and family history, as well as patient preference.